Benzinga's Small Cap Movers for Monday February 4, 2013
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
Shares of Cleveland BioLabs (NASDAQ: CBLI), the Buffalo, NY biotechnology company, rose 12.5% Monday on 4 times average volume.
Cleveland BioLabs was the subject of a positive Seeking Alpha article on Monday.
Cleveland BioLabs closed at $1.79 on Monday.
EDAP (NASDAQ: EDAP), the Lyon, France developer of therapeutic ultrasound equipment, rose 11% Monday on 5.5 times average volume.
EDAP announced Friday the submission of its PMA application to the FDA on January 31, 2013 for the Company's Ablatherm-HIFU for treatment of low risk, localized prostate cancer.
EDAP closed at $3.38 on Monday.
Shares of Delcath Systems (NASDAQ: DCTH), the New York City specialty pharmaceutical and medical device company, rose 8% Monday on almost 7 times average volume.
Delcath announced Monday that the Institut für das Entgeltsystem im Krankenhaus (InEk), the German federal reimbursement agency, has established a reimbursement pathway for the treatment of patients with liver metastases with the Delcath Hepatic CHEMOSAT® Delivery System for melphalan hydrochloride. The decision by the InEK followed an endorsement by the German Radiology Association, which prompted 47 cancer centers throughout Germany to submit applications under the Neue Untersuchungs- und Behandlungsmethoden (NUB) scheme for new technology reimbursement at specific hospitals.
Delcath Systems closed at $1.63 on Monday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.